alexa Tumour Suppressors and Cellular Senescence | OMICS International
ISSN: 2576-1471
Journal of Cell Signaling

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Tumour Suppressors and Cellular Senescence

Marta Benedekova, Ruchi Kumari and Parmjit S Jat*

MRC Prion Unit at UCL, Institute of Prion Diseases Queen Square London WC1N 3BG, UK

*Corresponding Author:
Parmjit S Jat
MRC Prion Unit at UCL, Institute of Prion Diseases
Queen Square London WC1N 3BG UK
E-mail: [email protected]

Received date: June 07, 2017; Accepted date: June 16, 2017; Published date: June 26, 2017

Citation: Benedekova M, Kumari R, S Jat P (2017) Tumour Suppressors and Cellular Senescence. J Cell Signal 2:155.

Copyright: © 2017 Benedekova M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Cell Signaling

Commentary

Cellular senescence is a stable growth arrest that normal human diploid fibroblasts undergo after a finite number of divisions, as a result of progressive shortening of telomeres and other genotoxic as well as non-genotoxic stresses. It is an example of antagonistic pleiotropy, as it plays an important role in tumour suppression during early life whereas later in life, it leads to deleterious traits, such as disrupted tissue function, thereby promoting organismal ageing and age-related diseases. Elucidating and understanding the signalling pathways involved in regulating the senescent state, is therefore of great biological importance.

Cellular senescence is a stable growth arrest, that normal human diploid fibroblasts undergo after a finite number of divisions [1], as a result of progressive shortening of telomeres [2]. However, further stressors such as oncogenic activation, DNA damage, oxidative stress and other non-genotoxic stresses were later found to also trigger this arrested state [3]. Senescence is an example of antagonistic pleiotropy, playing an important role in tumour suppression during early life, as it is a natural barrier to carcinogenesis. Later in life, it leads to deleterious traits, such as disrupted tissue function, consequently promoting organismal ageing and age-related diseases. Hence, elucidating the signalling pathways involved in regulating the senescent state is of great biological importance.

Multiple stimuli are known to activate the p53/p21 and p16/pRB tumour suppressor pathways, which have clearly been established to mediate senescence; however, the critical downstream targets have yet to be determined (Figure 1) [4]. Furthermore, it is unclear whether these pathways function in parallel or are linear, in establishing senescence [5]. p21WAF1, a downstream target of the p53 protein, is an inhibitor of cyclin-dependent kinases and can activate the pRB tumour suppressor pathway, by inhibiting cyclin D/CDK4,6 kinases [6]. p16INK4a inhibitor is also able to activate the pRB pathway, independently of the p53 pathway [5].

cell-signaling-Schematic-illustration

Figure 1: Schematic illustration of the signalling pathways involved in regulating cellular senescence.

The specific cell type and whether the studies are conducted on human or mouse cells are important factors for determining which of the signalling pathways has a greater significance in inducing senescence. Fundamentally, the importance of these two pathways in establishing senescence has been demonstrated by reversing senescence by reducing p16INK4a levels and/or inactivating p53 [7-9].

Extensive research has been conducted to establish the downstream targets of the p53 and pRB pathways. One of these studies, conducted by Blagosklonny and colleagues, demonstrated that conversion of quiescence, a reversible growth arrest, to senescence, a stable growth arrest, was the result of active mTOR (mechanistic target of rapamycin) signalling, termed geroconversion [10]. mTOR forms two multiprotein complexes that regulate cell growth, energy metabolism, cell survival and the cytoskeleton [11]. Among other signalling pathways, mTOR is also regulated by stress-induced p53 signalling. Sustained mTOR activity mediates geroconversion, signifying a role for these complexes in senescence. These studies have shown that when mTOR is activated in growth arrested cells, they undergo senescence whereas inhibition of mTOR blocks entry into senescence [12-14]. How mTOR activation leads to senescence, is not known.

To establish the downstream targets of p53 and pRB, previous studies have also focussed on the DREAM complex [15-17]. P53 and pRB are central in controlling cell cycle progression [18]. An integral component, regulating gene expression throughout the cell cycle, proposed by DeCaprio and colleagues, is the DREAM complex (Figure 2).

cell-signaling-Upon-stimulation

Figure 2: The DREAM complex : Assembly of this complex is mediated by MuvB, comprising LIN9, 37, 52, 54 and RBBP4, binding with the RB family members (p130/p107)-E2F4-DP, leading to quiescence. Upon stimulation of cell cycle re-entry, p130/ p107 are phosphorylated, leading to their dissociation from the DREAM complex enabling MuvB to sequentially recruit B-MYB during S-phase and FOXM1 during G2/M phase, to promote cell cycle-dependent target gene expression. Expression of these target genes promotes transit through the cell cycle. During G2-phase, B-MYB undergoes phosphorylation-dependent degradation. Upon exposure to stimuli that repress cell cycle progression, LIN52 within MuvB is phosphorylated, promoting re-association of MuvB with p130/p107-E2F4-DP, to re-assemble the DREAM complex.

The function of this complex has been characterised in quiescence [15], which suggests a potential role in senescence, but this remains to be verified. Although it is clear how p53 and pRB activation lead to quiescence, a greater understanding of downstream transcription factors and target genes involved in establishing senescence is essential, to distinguish between senescence and quiescence.

The DREAM complex is composed of the p130/p107 pocket proteins, homologous to pRB, E2F4 transcription factor, its dimerization partner 1 (DP1), and the multi-vulval class B (MuvB) proteins (LIN9, LIN37, LIN52, LIN54 and RBBP4). In the active form, p130/p107 inhibit transcription required for cell cycle progression by binding to E2F4. Upon entry into the cell cycle, the MuvB core dissociates from the complex and sequentially recruits B-MYB and FOXM1 during S-phase and G2-phase, to promote late S-phase and mitotic gene expression, important for cell cycle progression (Figure 2). A link between the DREAM complex and senescence induction has been suggested by Litovchick et al. [16], using immortalised human BJhTERT skin fibroblasts. The DYRK1A protein kinase phosphorylates the Serine 28 residue of LIN52, enabling its interaction with p130/ p107, to form an active DREAM complex. Mutating Ser28-LIN52 to Ala28-LIN52, thereby inhibiting its phosphorylation, suppresses oncogenic Ras-induced senescence [16]. However, the DREAM complex does not comprise the pRB tumour suppressor protein, so it is possible that during senescence p130/p107 and pRB play differing functions. Furthermore, Lowe and colleagues have shown that in another cell system, inhibiting only the pRB pocket protein bypasses Ras-induced senescence [19]. While these differences are likely to be the result of using different cells, the different functions of the DREAM complex and RB require further investigation [20].

Emerging evidence indicates that the epigenetic machinery might also play a key role in the induction and regulation of cellular senescence in disease-associated cells. An interesting observation in cancer cells suggests that genetic depletion of histone methyltransferases SUV39H1and G9a, is able to prevent cell growth, and results in profound morphological changes with reduction of telomerase activity and shortened telomeres [21]. In fact, knocking down of SUV39H1 in cells led to a substantial increase within G2/M, whereas knocking down of G9a showed an increased DNA content and aberrant karyotype. As genetic depletion of SUV39H1/2 results in widespread genomic instability [22] and both G9a and SUV39H1 serve as the key H3K9 modifiers in mammals [23], it would be interesting to investigate the link between H3K9me, a key heterochromatin mark, and cell cycle regulation. Strikingly, since recent observations indicate that G9a also interacts with DNA methyltransferases (DNMTs) and protects DNA methylation [24], another heterochromatin mark in mammals, cell cycle arrest and senescence might be strongly associated with euchromatin/heterochromatin turnover.

Identifying downstream targets of the p53 and pRB signalling pathways, as well as the role of epigenetics in regulating cellular senescence is integral to finding the causal factors and laying the foundation for a better understanding of the signalling circuits underlying cellular senescence. Multiple mechanisms could be involved in regulating senescence, as the responses vary between cell-types, tissues and species. Future research should additionally be targeted towards characterising these differences. The established signalling components could represent novel, important and direct targets for developing new therapies that promote healthier ageing and increase vitality of the older population through stimulating regeneration, repair and wound healing, while retaining the tumour suppressor properties of senescence, if possible. The key components will also be new therapeutic cancer targets, for developing small molecule inhibitors and activators aimed at inducing senescence in tumours. They may also be relevant for treatment of neurodegenerative disease, as it has been proposed that senescence in central nervous system cells may be a contributing factor towards neurodegeneration, due to secretion of pro-inflammatory senescence-associated secretory phenotype proteins [25-27].

Acknowledgements

We thank ‘Reviewer 2’ for his insightful critique and for recommending that we insert the paragraph he provided on the role of epigenetics in senescence. We thank Richard Newton for graphics and apologise to authors whose work is not discussed or cited due to space constraints. MB is a Cell Biology MSci student, at University College London. RK is a Commonwealth Scholar (INCS-2014-212).

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 415
  • [From(publication date):
    September-2017 - Jul 19, 2018]
  • Breakdown by view type
  • HTML page views : 366
  • PDF downloads : 49
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7